# SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
Canonical URL: https://biopharmsignal.com/news/SABS/sab-bio-reports-q1-2026-financial-results-and-recent-business-highlights
Ticker: SABS
Company: SAB Biotherapeutics
Source: SAB Biotherapeutics
Published: 2026-05-12 11:30 EST
Original Source URL: https://ir.sab.bio
## Summary

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in

## Article Body
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in
## Recent Company News
- 2026-05-29 12:00 EST — [SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting](https://biopharmsignal.com/news/SABS/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-association-s-2026-scientific-sessions-and-focis-2026-annual-meeting) — Source: SAB Biotherapeutics
- 2026-05-12 11:30 EST — [SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/SABS/sab-bio-reports-q1-2026-financial-results-and-recent-business-highlights) — Source: SAB Biotherapeutics
- 2026-05-05 12:30 EST — [SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET](https://biopharmsignal.com/news/SABS/sab-bio-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-may-12-2026-08-30-am-et) — Source: SAB Biotherapeutics
- 2026-04-22 11:00 EST — [SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026](https://biopharmsignal.com/news/SABS/sab-bio-presents-additional-clinical-and-mechanistic-data-from-sab-142-phase-1-trial-in-adult-patients-with-established-autoimmune-type-1-diabetes-at-ids-2026) — Source: SAB Biotherapeutics
- 2026-04-15 12:00 EST — [SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress](https://biopharmsignal.com/news/SABS/sab-bio-to-present-additional-data-supporting-the-unique-profile-of-sab-142-at-the-2026-immunology-of-diabetes-society-congress) — Source: SAB Biotherapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)